Anti-LRP4 antibodies were detected in the serum of approximately 9.2% of patients with double-seronegative MG. This frequency is intermediate compared with 2 recent studies showing anti-LRP4 antibodies in 2% and 50% of patients with double-seronegative MG from different geographic locations. Together, these observations indicate that LRP4 is another autoantigen in patients with MG, and anti-LRP4 autoantibodies may be pathogenic through different immunopathogenic processes.
Department of Neurology, Institute of Molecular Medicine and Genetics, Georgia Health Sciences University, 1120 15th St, Augusta, GA 30912, USA.
Arch Neurol. 2012 Apr;69(4):445-51
© Galenicom 1999-2013